128 related articles for article (PubMed ID: 17043020)
1. Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome.
Langebrake C; Klusmann JH; Wortmann K; Kolar M; Puhlmann U; Reinhardt D
Haematologica; 2006 Nov; 91(11):1473-80. PubMed ID: 17043020
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
3. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome.
Raspadori D; Damiani D; Michieli M; Stocchi R; Gentili S; Gozzetti A; Masolini P; Michelutti A; Geromin A; Fanin R; Lauria F
Haematologica; 2002 Nov; 87(11):1135-40. PubMed ID: 12414342
[TBL] [Abstract][Full Text] [Related]
4. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
5. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Kroell T; Pfister K; Schmetzer H
Ann Hematol; 2005 May; 84(5):287-97. PubMed ID: 15592672
[TBL] [Abstract][Full Text] [Related]
6. Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis.
Gadgeel M; AlQanber B; Buck S; Taub JW; Ravindranath Y; Savaşan S
Ann Hematol; 2021 Jul; 100(7):1695-1700. PubMed ID: 33890142
[TBL] [Abstract][Full Text] [Related]
7. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
[TBL] [Abstract][Full Text] [Related]
8. [Comparative study on clinical features between TEL-AML1 positive and negative childhood acute lymphoblastic leukemia].
Guo X; Li Q; Zhu YP; Zhou CY; Gao J; Li XH; Pan LL; Li FY; Tian X; Liu HT
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Oct; 24(5):560-3. PubMed ID: 17922427
[TBL] [Abstract][Full Text] [Related]
9. [Down's syndrome and leukemia].
Bermúdez Cortés M; Verdeguer Miralles A; Jovaní Casano C; Cañete Nieto A; Fernández JM; Ferris Tortajada J; Castel Sánchez V
An Esp Pediatr; 1998 Jun; 48(6):593-8. PubMed ID: 9662842
[TBL] [Abstract][Full Text] [Related]
10. Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens.
Kalina T; Vaskova M; Mejstrikova E; Madzo J; Trka J; Stary J; Hrusak O
BMC Cancer; 2005 Apr; 5():38. PubMed ID: 15826304
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic progenitor cell deficiency in fetuses and children affected by Down's syndrome.
Holmes DK; Bates N; Murray M; Ladusans EJ; Morabito A; Bolton-Maggs PH; Johnston TA; Walkenshaw S; Wynn RF; Bellantuono I
Exp Hematol; 2006 Dec; 34(12):1611-5. PubMed ID: 17157155
[TBL] [Abstract][Full Text] [Related]
12. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice.
Yanagida M; Osato M; Yamashita N; Liqun H; Jacob B; Wu F; Cao X; Nakamura T; Yokomizo T; Takahashi S; Yamamoto M; Shigesada K; Ito Y
Oncogene; 2005 Jun; 24(28):4477-85. PubMed ID: 15856017
[TBL] [Abstract][Full Text] [Related]
13. [Expression of cell adhesion molecules in acute leukemia cell].
Ju X; Peng M; Xu X; Lu S; Li Y; Ying K; Xie Y; Mao Y; Xia F
Zhonghua Xue Ye Xue Za Zhi; 2002 Nov; 23(11):581-4. PubMed ID: 12482342
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of CD56 antigen expression in acute myeloid leukemia.
Di Bona E; Sartori R; Zambello R; Guercini N; Madeo D; Rodeghiero F
Haematologica; 2002 Mar; 87(3):250-6. PubMed ID: 11869936
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
[TBL] [Abstract][Full Text] [Related]
16. GATA1 mutations in acute leukemia in children with Down syndrome.
Magalhães IQ; Splendore A; Emerenciano M; Figueiredo A; Ferrari I; Pombo-de-Oliveira MS
Cancer Genet Cytogenet; 2006 Apr; 166(2):112-6. PubMed ID: 16631466
[TBL] [Abstract][Full Text] [Related]
17. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
[TBL] [Abstract][Full Text] [Related]
18. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
Nguyen DH; Ball ED; Varki A
Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
[TBL] [Abstract][Full Text] [Related]
19. Expression of the 67-kDa laminin receptor in acute myeloid leukemia cells mediates adhesion to laminin and is frequently associated with monocytic differentiation.
Montuori N; Selleri C; Risitano AM; Raiola AM; Ragno P; Del Vecchio L; Rotoli B; Rossi G
Clin Cancer Res; 1999 Jun; 5(6):1465-72. PubMed ID: 10389934
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic value of early treatment response in children with acute myeloid leukemia].
Tie LJ; Gu LJ; Song DL; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J; Wang YP; Zou JY
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(26):1837-40. PubMed ID: 17054861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
